Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
about
A perspective on anti-EGFR therapies targeting triple-negative breast cancerFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceMicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras.MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.The epidermal growth factor receptor (EGFR / HER-1) gatekeeper mutation T790M is present in European patients with early breast cancer.Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.How interacting pathways are regulated by miRNAs in breast cancer subtypes.Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.Development and clinical application of an integrative genomic approach to personalized cancer therapyIs it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.Emerging EGFR antagonists for breast cancer.Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast CancerAn aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.The Dawning of Translational Breast Cancer: From Bench to Bedside.Therapeutic landscape in mutational triple negative breast cancer
P2860
Q28069867-42A308DF-5BF2-4144-87F4-849E512B1620Q28077347-25C63538-0256-4FD5-ADE5-63BB054AE1C2Q33622710-4A99B63E-CD29-44A8-8667-54B882AA5F1EQ34221882-BF073117-46E9-48D7-8EC3-1FEBCCF45A0AQ34441761-2CA2C58E-A519-4413-A1B3-54B95EE0EBD3Q34654793-57A25144-C25B-4650-91AD-E0629E4D3E21Q34978420-6EFA5AE7-32E4-46F4-897C-59468CFF3C46Q35602598-FE7FADC7-C5C6-4976-BDA1-EAB5B6564EB6Q35744220-1E6B0914-F992-4460-9858-EC08B8BE6231Q35833567-9C401F7E-E2FA-45A9-9FCA-18F9BCB034B6Q35853834-DA16AF37-3FC1-4D3B-BFEC-5FAC6E16046EQ36276533-0A331EC2-DB48-489F-8564-022CC3B6FCBAQ36495170-A6790B58-40C5-4B7D-B274-0919A58AF2D3Q36954557-51B45450-F3A7-45E9-B432-8BABB6CEC876Q37468081-A999ABE6-EECB-4289-91BF-A26AA4CBF197Q37687445-9BA46AE7-431C-4C65-8845-2FE8DAC3FF2EQ38211951-F0A16361-D4EA-42D9-A443-37788D18F952Q38378354-FE4EE0A0-4A4A-48C6-99EF-92013950F1E9Q38974959-B630543D-14D2-46D6-81C9-0606A37943F8Q40953806-3B51A2F7-7D89-400B-A6F2-9A20435A55A2Q48239804-2578AEBB-8AD3-4810-8605-8A01EDA9B83AQ48240280-7FB0434F-598B-4D68-B2B3-64980E1A1BC9Q49544424-35FE5FD6-DE73-4763-B436-0FAF0208E3AFQ57109569-8AABC478-55B9-468B-A45E-668B0A7709E4
P2860
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Mutations in EGFR, BRAF and RA ...... cancers from Caucasian women.
@en
Mutations in EGFR, BRAF and RA ...... cancers from Caucasian women.
@nl
type
label
Mutations in EGFR, BRAF and RA ...... cancers from Caucasian women.
@en
Mutations in EGFR, BRAF and RA ...... cancers from Caucasian women.
@nl
prefLabel
Mutations in EGFR, BRAF and RA ...... cancers from Caucasian women.
@en
Mutations in EGFR, BRAF and RA ...... cancers from Caucasian women.
@nl
P2093
P2860
P50
P1476
Mutations in EGFR, BRAF and RA ...... cancers from Caucasian women.
@en
P2093
A C Vargas
M C Cummings
P T Simpson
S Cocciardi
P2860
P2888
P304
P356
10.1007/S10549-013-2798-1
P407
P577
2013-12-07T00:00:00Z
P6179
1024615719